We are pleased to announce that Prof. Dr. Jeremy Carlier has been appointed Editor-in-Chief of the “Pharmacology and Drug Metabolism” Section in Metabolites (ISSN: 2218-1989).
Prof. Dr. Carlier obtained a Ph.D. in analytical chemistry and forensic toxicology from Claude Bernard University Lyon 1, France, in 2014, and is currently a researcher and toxicologist in the Section of Legal Medicine within the Dept. of Biomedical Sciences and Public Health at Marche Polytechnic University in Italy. In 2022, he achieved the National Scientific Qualification as an Associate Professor of Legal Medicine, granted by the Italian Ministry of University and Research.
His research focuses on the detection and the metabolism of drugs of abuse and pharmaceuticals for forensic and clinical applications. As of September 2024, he has co-authored 60 peer-reviewed articles, with 42 as the main author (first/last/corresponding), achieving an h-index of 25 (Google Scholar). He has presented his work (45 oral presentations/posters) at conferences organized by national and international scientific societies in analytical chemistry, toxicology, and forensic sciences. He serves on various editorial committees and has reviewed numerous manuscripts for scientific journals including The AAPS Journal, Archives of Toxicology, Communications Biology – Nature, Talanta, and Trends in Analytical Chemistry.
The following is a short Q&A with Prof. Dr. Jeremy Carlier, who shared his vision for the journal with us, as well as his views on the research area:
1. What appealed to you about the journal that made you want to take on the role of Section Editor-in-Chief of the “Pharmacology and Drug Metabolism” Section?
I am a diligent reader of Metabolites and have published several articles in this journal. As far as I can judge, Metabolites provides high-quality research articles in my field of expertise, and I am eager to contribute more significantly to its progress.
2. How do you feel about being an Editorial Board Member of Metabolites?
There are challenges, as journals that charge for publication are not always viewed in a positive light, but I am confident we can elevate Metabolites to new levels.
3. What do you think of the development of open access in the publishing field?
With the development of social networking services that allow easy sharing of published articles, journals are legitimately seeking alternative income sources to sustain their operations, making open access with article-processing charges increasingly poised to gain traction. This approach clearly has the advantage of facilitating and normalizing access to research data. However, certain journals may exploit this model to prioritize profit over quality and ethical standards. It is crucial that we ensure quality prevails in Metabolites.
4. What does the future of this field of research look like?
There are still many gaps to fill in our understanding of drug metabolism and pharmacology, especially with the continuous emergence of new psychoactive substances on the illicit drug market. Advancements in technology, such as artificial intelligence, along with a growing understanding of molecular biology, genomics, and data science are primed to drive major breakthroughs.
We warmly welcome Prof. Dr. Jeremy Carlier as the Editor-in-Chief of the Section “Pharmacology and Drug Metabolism”, and we look forward to him leading Metabolites to many more milestones.
Metabolites Editorial Office
